0001214659-19-008005.txt : 20191226
0001214659-19-008005.hdr.sgml : 20191226
20191226181506
ACCESSION NUMBER: 0001214659-19-008005
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191223
FILED AS OF DATE: 20191226
DATE AS OF CHANGE: 20191226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Christensen Jamie
CENTRAL INDEX KEY: 0001599324
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35921
FILM NUMBER: 191311346
MAIL ADDRESS:
STREET 1: C/O MIRATI THERAPEUTICS, INC.
STREET 2: 9393 TOWNE CENTRE DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mirati Therapeutics, Inc.
CENTRAL INDEX KEY: 0001576263
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462693615
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9393 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-332-3410
MAIL ADDRESS:
STREET 1: 9393 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
marketforms-47018.xml
PRIMARY DOCUMENT
X0306
4
2019-12-23
0001576263
Mirati Therapeutics, Inc.
MRTX
0001599324
Christensen Jamie
C/O MIRATI THERAPEUTICS, INC.
9393 TOWNE CENTRE DRIVE, STE 200
SAN DIEGO
CA
92121
false
true
false
false
EVP, Chief Scientific Officer
Common Stock
2019-12-23
4
M
false
2499
5.50
A
11658
D
Common Stock
2019-12-23
4
S
false
2499
125.00
D
9159
D
Common Stock
2019-12-23
4
M
false
4167
5.40
A
13326
D
Common Stock
2019-12-23
4
S
false
4167
125.00
D
9159
D
Employee Stock Option (Right to Buy)
5.50
2019-12-23
4
M
false
2499
0
D
2026-10-26
Common Stock
2499
15003
D
Employee Stock Option (Right to Buy)
5.40
2019-12-23
4
M
false
4167
0
D
2027-01-25
Common Stock
4167
28125
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2018.
Includes 256 shares acquired under the ESPP Purchase on 05/31/2019 and 114 shares acquired under the ESPP purchase on 11/29/2019.
1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested.
/s/ Vickie Reed, Attorney-in-Fact
2019-12-26